Intas Pharmaceuticals offered $1.5bn for 3 divisions of Teva’s in Europe

India-based pharmaceutical group Intas Pharmaceuticals reportedly offered $1.5bn for the European parts of Teva’s women’s health, oncology and pain management divisions in Europe. Intas is said to have already entered into agreements with banks and Indian and international investment funds, including ICICI, Axis, Citi, Bank of Tokyo, Mitsubishi UFJ, HSBC, in order to finance the deal. Intas Pharmaceuticals is the largest Indian private pharmaceutical group, generating in 2016 sales equivalent – in euros – to €877m, with a net profit of €110m. Importantly, Teva last year sold Intas Pharmaceuticals the UK and Irish divisions of Actavis Generics for GBP603m.
(Source: The Economic Times)